|
|
Prevalence of cardiovascular diseases in China |
Jun-Jie XIAO MD,Yi-Han CHEN MD, PhD, |
Department of Cardiology,
Tongji Hospital, Tongji University School of Medicine, Shanghai 200065,
China;Key Laboratory of Arrhythmias
of Ministry of Education, Tongji University, Shanghai 200065, China;Institute of Medical
Genetics, Tongji University, Shanghai 200065, China; |
|
|
Abstract Cardiovascular diseases (CVD) cause one third of all deaths in China, and the number is anticipated to double by 2020. They also greatly result in disability and adjusted life year loss. The prevalence of CVD has become a new burden for China, due to an aging population, smoking, and changes in dietary habits and lifestyles. As the largest developing country, China needs to tailor her own national policies for managing CVD with full consideration of epidemiology, local needs, and affordability. Smoking cessation, increased physical activity, control of hypertension and hypercholesterolemia, and maintenance of a “traditional Chinese” diet should be important strategies for reducing the burden of CVD in China. Health officials in China should take their responsibilities to implement educational and preventive measures seriously.
|
Keywords
cardiovascular diseases
prevalence
China
risk factors
prevention
|
Issue Date: 05 March 2010
|
|
|
Wu Y, Huxley R, Li L, Anna V, Xie G, Yao C, Woodward M, Li X, Chalmers J, Gao R, Kong L, Yang X. Prevalence,awareness, treatment, and control of hypertension in China: data fromthe China national nutrition and health survey 2002. Circulation, 2008, 118(25): 2679–2686
doi: 10.1161/CIRCULATIONAHA.108.788166
|
|
Mark D B, Van de Werf F J, Simes R J, White H D, Wallentin L C, Califf R M, Armstrong P W; VIGOUR Group for the VG. Cardiovascular disease on a global scale: defining the path forwardfor research and practice. Eur Heart J, 2007, 28(21): 2678–2684
doi: 10.1093/eurheartj/ehm411
|
|
Klein W. Cardiovascular disease at the turn of the millennium:focus on Europe. Eur Heart J Suppl, 2001, 3(Supplement M): M2–M6
doi: 10.1016/S1520-765X(01)90075-6
|
|
Hua W, Zhang L F, Wu Y F, Liu X Q, Guo D S, Zhou H L, Gou Z P, Zhao L C, Niu H X, Chen K P, Mai J Z, Chu L N, Zhang S. Incidence of sudden cardiac death inChina: analysis of 4 regional populations. J Am Coll Cardiol, 2009, 54(12): 1110–1118
doi: 10.1016/j.jacc.2009.06.016
|
|
Yusuf S, Reddy S, Ounpuu S, Anand S. Globalburden of cardiovascular diseases: part I: general considerations,the epidemiologic transition, risk factors, and impact of urbanization. Circulation, 2001, 104(22): 2746–2753
doi: 10.1161/hc4601.099487
|
|
He Y, Jiang B, Wang J, Feng K, Chang Q, Zhu S, Fan L, Li X, Hu F B. BMI versus the metabolic syndrome in relation to cardiovascularrisk in elderly Chinese individuals. DiabetesCare, 2007, 30(8): 2128–2134
doi: 10.2337/dc06-2402
|
|
He J, Gu D, Wu X, Reynolds K, Duan X, Yao C, Wang J, Chen C S, Chen J, Wildman R P, Klag M J, Whelton P K. Major causes of death among men and women in China. N Engl J Med, 2005, 353(11): 1124–1134
doi: 10.1056/NEJMsa050467
|
|
Muntner P, Gu D, Wu X, Duan X, Wenqi G, Whelton P K, He J. Factors associatedwith hypertension awareness, treatment, and control in a representativesample of the Chinese population. Hypertension, 2004, 43(3): 578–585
doi: 10.1161/01.HYP.0000116302.08484.14
|
|
Critchley J, Liu J, Zhao D, Wei W, Capewell S. Explaining the increase incoronary heart disease mortality in Beijing between 1984 and 1999. Circulation, 2004, 110(10): 1236–1244
doi: 10.1161/01.CIR.0000140668.91896.AE
|
|
Zhang X H, Lu Z L, Liu L. Coronary heart disease in China. Heart, 2008, 94(9): 1126–1131
doi: 10.1136/hrt.2007.132423
|
|
Wu Z, Yao C, Zhao D, Wu G, Wang W, Liu J, Zeng Z, Wu Y. Sino-MONICA project: a collaborativestudy on trends and determinants in cardiovascular diseases in China,Part I: morbidity and mortality monitoring. Circulation, 2001, 103(3): 462–468
|
|
Girmatsion Z, Biliczki P, Bonauer A, Wimmer-Greinecker G, Scherer M, Moritz A, Bukowska A, Goette A, Nattel S, Hohnloser S H, Ehrlich J R. Changes in microRNA-1 expression and I(K1) up-regulation in humanatrial fibrillation. Heart Rhythm, 2009, 6(12): 1802–1809
doi: 10.1016/j.hrthm.2009.08.035
|
|
Coronel R, Langerveld J, Boersma L V, Wever E F, Bon L, van Dessel P F, Linnenbank A C, van Gilst W H, Ernst S M, Opthof T, van Hemel N M. Left atrial pressure reduction for mitral stenosis reverses leftatrial direction dependent conduction abnormalities. Cardiovasc Res, 2009,
doi: 10.1093/CVR/CVP374
doi: 10.1093/CVR/CVP374
|
|
Virtanen J K, Mursu J, Voutilainen S, Tuomainen T P. Serum long-chain n-3 polyunsaturated fatty acids andrisk of hospital diagnosis of atrial fibrillation in men. Circulation, 2009, 120(23): 2315–2321
doi: 10.1161/CIRCULATIONAHA.109.852657
|
|
Hu D, Sun Y. Epidemiology,risk factors for stroke, and management of atrial fibrillation inChina. J Am Coll Cardiol, 2008, 52(10): 865–868
doi: 10.1016/j.jacc.2008.05.042
|
|
Zhou Z, Hu D. An epidemiologicalstudy on the prevalence of atrial fibrillation in the Chinese populationof mainland China. J Epidemiol, 2008, 18(5): 209–216
doi: 10.2188/jea.JE2008021
|
|
He J, Gu D, Reynolds K, Wu X, Muntner P, Zhao J, Chen J, Liu D, Mo J, Whelton P K. Serum total and lipoproteincholesterol levels and awareness, treatment, and control of hypercholesterolemiain China. Circulation, 2004, 110(4): 405–411
doi: 10.1161/01.CIR.0000136583.52681.0D
|
|
Zhang S. Atrial fibrillation in mainland China: epidemiology andcurrent management. Heart, 2009, 95(13): 1052–1055
doi: 10.1136/hrt.2008.146589
|
|
Pascual-Figal D A, Ordonez-Llanos J, Tornel P L, Vazquez R, Puig T, Valdes M, Cinca J, de Luna A B, Bayes-Genis A. Soluble ST2 for predicting sudden cardiac death in patientswith chronic heart failure and left ventricular systolic dysfunction. J Am Coll Cardiol, 2009, 54(23): 2174–2179
doi: 10.1016/j.jacc.2009.07.041
|
|
George A L Jr. Common genetic variants in sudden cardiac death. Heart Rhythm, 2009, 6(11 Suppl): S3–9
doi: 10.1016/j.hrthm.2009.08.024
|
|
Colquhoun S M, Carapetis J R, Kado J H, Steer A C. Rheumatic heart disease and its control in the Pacific. Expert Rev cardiovas Ther, 2009, 7(12): 1517–1524
doi: 10.1586/erc.09.145
|
|
Zhimin W, Yubao Z, Lei S, Xianliang Z, Wei Z, Li S, Hao W, Jianjun L, Detrano R, Rutai H. Prevalence of chronic rheumaticheart disease in Chinese adults. Int JCardiol, 2006, 107(3): 356–359
doi: 10.1016/j.ijcard.2005.03.048
|
|
Knirsch W, Zingg W, Bernet V, Balmer C, Dimitropoulos A, Pretre R, Bauersfeld U, Latal B. Determinants of body weightgain and association with neurodevelopmental outcome in infants operatedfor congenital heart disease. InteractCardiovasc Thorac Surg, 2009,
doi: 10.1510/icvts.2009.216135
doi: 10.1510/icvts.2009.216135
|
|
Yang X Y, Li X F, Lu X D, Liu Y L. Incidence of congenital heart disease in Beijing, China. Chin Med J (Engl), 2009, 122(10): 1128–1132
|
|
Callow A D. Cardiovascular disease 2005-the global picture. Vascul Pharmacol, 2006, 45(5): 302–307
doi: 10.1016/j.vph.2006.08.010
|
|
Gu D, Reynolds K, Wu X, Chen J, Duan X, Muntner P, Huang G, Reynolds R F, Su S, Whelton P K, He J. Prevalence, awareness, treatment,and control of hypertension in china. Hypertension, 2002, 40(6): 920–927
doi: 10.1161/01.HYP.0000040263.94619.D5
|
|
Yusuf S, Reddy S, Ounpuu S, Anand S. Globalburden of cardiovascular diseases: Part II: variations in cardiovasculardisease by specific ethnic groups and geographic regions and preventionstrategies. Circulation, 2001, 104(23): 2855–2864
doi: 10.1161/hc4701.099488
|
|
Gu D, Gupta A, Muntner P, Hu S, Duan X, Chen J, Reynolds R F, Whelton P K, He J. Prevalence of cardiovascular disease risk factor clusteringamong the adult population of China: results from the InternationalCollaborative Study of Cardiovascular Disease in Asia (InterAsia). Circulation, 2005, 112(5): 658–665
doi: 10.1161/CIRCULATIONAHA.104.515072
|
|
Liu L. Cardiovascular diseases in China. Biochem Cell Biol, 2007, 85(2): 157–163
doi: 10.1139/O07-004
|
|
Cheng T O. The current state of cardiology in China. Int J Cardiol, 2004, 96(3): 425–439
doi: 10.1016/j.ijcard.2003.10.011
|
|
Howard B V, Comuzzie A, Devereux R B, Ebbesson S O, Fabsitz R R, Howard W J, Laston S, Maccluer J W, Silverman A, Umans J G, Wang H, Weissman N J, Wenger C R. Cardiovascular disease prevalence and its relation torisk factors in Alaska Eskimos. Nutr MetabCardiovasc Dis, 2009,
doi: 10.1016/j
doi: 10.1016/j
|
|
Liu M, Wu B, Wang W Z, Lee L M, Zhang S H, Kong L Z. Stroke in China: epidemiology, prevention, and managementstrategies. Lancet Neurol, 2007, 6(5): 456–464
doi: 10.1016/S1474-4422(07)70004-2
|
|
Berger J S, Bhatt D L, Steinhubl S R, Shao M, Steg P G, Montalescot G, Hacke W, Fox K A, Lincoff A M, Topol E J, Berger P B. Smoking, clopidogrel, and mortality in patients with establishedcardiovascular disease. Circulation, 2009, 120(23): 2337–2344
doi: 10.1161/CIRCULATIONAHA.109.866533
|
|
Hu J, Wallace D C, Jones E, Liu H. Cardiometabolic health of Chinese older adults with diabetesliving in Beijing, China. Public HealthNurs, 2009, 26(6): 500–511
doi: 10.1111/j.1525-1446.2009.00810.x
|
|
Cheng T O. Smoking and diabetes in Chinese men. Postgrad Med J, 2001, 77(910): 551
doi: 10.1136/pmj.77.910.551a
|
|
Gu D, Wu X, Reynolds K, Duan X, Xin X, Reynolds R F, Whelton P K, He J. Cigarette smoking and exposureto environmental tobacco smoke in China: the international collaborativestudy of cardiovascular disease in Asia. Am J Public Health, 2004, 94(11): 1972–1976
doi: 10.2105/AJPH.94.11.1972
|
|
McGuire K A, Janssen I, Ross R. Ability of physical activityto predict cardiovascular disease beyond commonly evaluated cardiometabolicrisk factors. Am J Cardiol, 2009, 104(11): 1522–1526
doi: 10.1016/j.amjcard.2009.07.023
|
|
Fu F H, Fung L. The cardiovascularhealth of residents in selected metropolitan cities in China. Prev Med, 2004, 38(4): 458–467
doi: 10.1016/j.ypmed.2003.11.022
|
|
Kelly T N, Gu D, Chen J, Huang J F, Chen J C, Duan X, Wu X, Yau C L, Whelton P K, He J. Hypertension subtype andrisk of cardiovascular disease in Chinese adults. Circulation, 2008, 118(15): 1558–1566
doi: 10.1161/CIRCULATIONAHA.107.723593
|
|
Lee D E, Cooper R S. Recommendations for global hypertension monitoring and prevention. Curr Hypertens Rep, 2009, 11(6): 444–449
doi: 10.1007/s11906-009-0075-9
|
|
Tang J L, Hu Y H. Drugs forpreventing cardiovascular disease in China. BMJ, 2005, 330(7492): 610–611
doi: 10.1136/bmj.330.7492.610
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|